Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that develops from B cells, a type of white blood cell that normally helps fight infections. It accounts for roughly 3% to 6% of all non-Hodgkin lymphomas, and the five-year survival rate is about 50%. Most people are diagnosed in their 60s or 70s, and men are affected about three times more often than women.
The name comes from the “mantle zone,” a specific region surrounding the centers of lymph nodes where these B cells normally live. When these cells grow out of control, they can spread to lymph nodes throughout the body, the bone marrow, blood, spleen, and other organs.
What Causes It at the Genetic Level
Nearly all cases of MCL are driven by a specific genetic error: a swap of material between chromosomes 11 and 14. This swap, called a translocation, places a gene called CCND1 next to a powerful switch that’s normally used to activate immune system genes. The result is that the cell produces far too much of a protein called cyclin D1, which acts like a stuck accelerator pedal on cell growth. The cell divides when it shouldn’t, and those divisions accumulate over time into lymphoma.
In rare cases where this classic translocation isn’t present, similar mechanisms are at work. Researchers have found that enhancer regions from immune system genes can land near related genes (CCND2 or CCND3), overproducing similar growth-driving proteins. The end result is the same: unchecked cell division.
Two Distinct Subtypes
MCL isn’t a single disease. It comes in two forms that behave very differently.
Classical (nodal) MCL is the more common and more aggressive form. It typically shows up with swollen lymph nodes in multiple areas of the body, often with elevated blood markers like LDH (a sign of rapid cell turnover). These tumors tend to carry more genetic damage overall and are more genomically complex. About 74% of patients with classical MCL need chemotherapy-based treatment right away at diagnosis.
Leukemic non-nodal MCL is a slower-growing form found mainly in the blood, bone marrow, and spleen, without significant lymph node swelling. It carries fewer genetic abnormalities and has a notably better outlook: three-year overall survival is 92%, compared to 69% for the classical type. Around 88% of patients with this form don’t need treatment at diagnosis and can be monitored with a watch-and-wait approach. Distinguishing between the two forms is important because it directly shapes treatment decisions and what you can expect going forward.
Common Signs and Symptoms
MCL most commonly involves lymph nodes, but extranodal spread is frequent. The gastrointestinal tract is one of the most common sites outside of lymph nodes, where involvement can appear as multiple polyp-like growths in the stomach or intestines. The Waldeyer ring (the ring of tissue in the back of the throat that includes the tonsils) is another frequent site. Bone marrow and peripheral blood involvement are common as well, and the cancer can sometimes spread to the lungs or central nervous system.
The symptoms people notice most often include painless swollen lymph nodes in the neck, armpits, or groin. Fatigue, unexplained weight loss, night sweats, and fevers are also typical. Some people develop digestive symptoms like bloating, nausea, or changes in bowel habits when the GI tract is involved. Because MCL is usually already widespread by the time it’s diagnosed, most people are at an advanced stage when they first learn they have it.
How MCL Is Diagnosed
Diagnosing MCL requires a tissue biopsy, usually from a lymph node, along with detailed testing of the cells’ surface markers. MCL cells have a characteristic pattern: they are positive for CD5, CD19, and CD20 (markers found on certain B cells) while being negative or very dim for CD23 and CD200. This specific combination helps pathologists distinguish MCL from other B-cell lymphomas that can look similar under a microscope, such as chronic lymphocytic leukemia or marginal zone lymphoma.
Confirming the cyclin D1 overexpression or the chromosome 11;14 translocation is typically the definitive step. Testing for a marker called SOX11 can also help classify the subtype. Classical MCL has high SOX11 expression, while the leukemic non-nodal form has very low levels.
Predicting How It Will Progress
Doctors use a scoring system called the Mantle Cell Lymphoma International Prognostic Index (MIPI) to estimate how the disease is likely to behave. It’s based on four factors: age, physical performance status, LDH levels, and white blood cell count. Based on these, patients fall into three groups. Low-risk patients (about 44% of cases) have the best outlook, with median survival not yet reached in studies. Intermediate-risk patients (35%) have a median survival around 51 months. High-risk patients (21%) have a median survival of about 29 months.
These numbers represent averages across large groups and can’t predict any individual’s outcome. Newer treatments have improved survival significantly since these scores were first developed.
Frontline Treatment Options
Treatment depends heavily on your age, overall fitness, and which subtype of MCL you have.
For younger, fit patients (generally 65 and under), the standard approach is aggressive: combination chemotherapy that includes a drug called cytarabine paired with the antibody rituximab, followed by a stem cell transplant using your own cells, then ongoing maintenance therapy with rituximab. A landmark trial showed that adding cytarabine to the initial chemotherapy regimen significantly improved outcomes compared to chemotherapy without it.
For older patients or those who aren’t candidates for intensive treatment, a gentler chemotherapy combination of bendamustine with rituximab has become a standard choice, supported by multiple randomized trials showing it works as well as more intensive regimens while being better tolerated. After this initial treatment, ongoing maintenance rituximab helps extend remission. Another option for this group is a combination of lenalidomide with rituximab, which avoids traditional chemotherapy entirely and can be used both for initial treatment and as ongoing maintenance.
When the Disease Comes Back
MCL frequently relapses, even after a good initial response. This is where newer targeted therapies have made the biggest difference. A class of drugs called BTK inhibitors blocks a signaling pathway that MCL cells depend on for survival. Four BTK inhibitors are currently approved: ibrutinib, zanubrutinib, acalabrutinib, and tirabrutinib. These are taken as daily pills and can produce durable responses, though resistance eventually develops in many patients.
For patients whose disease has progressed through BTK inhibitors and at least one other therapy, CAR-T cell therapy offers a powerful option. This treatment involves collecting your own immune cells, genetically engineering them in a lab to recognize and attack lymphoma cells, and infusing them back into your body. A product called lisocabtagene maraleucel (Breyanzi) is FDA-approved specifically for relapsed MCL. In a trial of 88 patients who had already failed multiple treatments including a BTK inhibitor, 72% achieved a complete response, meaning the cancer was undetectable.
Monitoring After Treatment
After achieving remission, regular follow-up is essential because MCL can return months or years later. A common approach is CT scans every six months for the first two years after treatment, with imaging after that point guided by symptoms or clinical findings rather than a fixed schedule. There are no MCL-specific surveillance guidelines that differ substantially from general non-Hodgkin lymphoma recommendations, so your oncologist will tailor the monitoring plan based on your subtype, initial risk category, and how deeply you responded to treatment.